Trial
NCT03093740
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Massachusetts General Hospital
Collaborators
—
Condition
Renal Failure Chronic
Intervention
Zepatier
Why stopped
Withdrew IRB application, never approved and no subjects enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-20